Myfotic Tablet

Mycophenolate Mofetil
360mg
Novartis India Ltd.
Pack size
Dispensing mode
Source
Agent
Retail Price 161.00 NPR

Available as:

Indications

Myfotic Tablet is used for: Prophylaxis of acute renal graft rejection, Prophylaxis of cardiac graft rejection, Liver Transplant

Adult Dose

Oral Prophylaxis of acute renal graft rejection Adult: 1 g bid starting within 72 hr of transplantation. Max: 2 g/day. Prophylaxis of cardiac graft rejection, Liver Transplant Adult: 1.5 g bid starting within 5 days after transplantation.

Child Dose

Kidney Transplant <3 months Safety and efficacy not established >3 months Prophylaxis of organ rejection in patients receiving allogeneic renal transplants MMF (suspension): 600 mg/m² PO q12hr; not to exceed 2 g/day MMF: BSA 1.25-1.5 m²: 750 mg capsule PO q12hr MMF: BSA >1.5 m²: 1 g capsule/tablet PO q12hr

Renal Dose

Renal impairment MMF: In severe renal impairment (glomerular filtration rate [GFR] <25 mL/min/1.73 m²), not to exceed 1 g q12hr No dosage adjustment needed in renal transplant patients experiencing delayed graft function postoperatively

Administration

Drug is taken on empty stomach 1 hour before or 2 hours after meals Once dosage is stabilized, MMF can be taken with food after kidney transplant

Contra Indications

Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome.

Precautions

Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia. Lactation: Unknown whether drug is excreted in breast milk; avoid using, or do not nurse

Pregnancy-Lactation

Interactions

Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.

Adverse Effects

Side effects of Mycophenolate Mofetil : >10% Hyperglycemia (44%),Hypercholesterolemia (41%),Hypomagnesemia (39%),Dyspnea (37%),Back pain (35%),Increased blood urea nitrogen (BUN) (35%),Leukopenia (34%),Pleural effusion (34%),Urinary tract infection (34%),Increasing frequency of cough (31%),Hypocalcemia (30%),Hypertension (28%),Abdominal pain (27%),Peripheral edema (27%),Anemia (26%),Fever (23%),Nausea (23%),Hyperkalemia (22%),Diarrhea (21%),Infection (21%),Headache (16%) 1-10% Melanoma (1.6-4.2%),Other malignancies (0.7-2.1%),Lymphoma (0.4-1%),Opportunistic infection (including herpes),Neutropenia,GI bleeding,Pulmonary fibrosis,Progressive multifocal leukoencephalopathy Potentially Fatal: Angioedema, anaphylaxis, fatal pulmonary fibrosis.

Mechanism of Action

Mycophenolic acid acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T- and B- lymphocytes.

Note

Myfotic 360mg Tablet manufactured by Novartis India Ltd.. Its generic name is Mycophenolate Mofetil. Myfotic is availble in Nepal. Farmaco Nepal drug index information on Myfotic Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Mycophenolate Mofetil :